Publicaties WCN-studies: dr. A. Mosterd

• Efficacy and safety of low-dose digoxin in patients with heart failure. Rationale and design of the DECISION trialEuropean Journal of Heart Failure - Mosterd, dr. A.; Alings, dr. A.M.W.; Schut, drs. A.; Schaap, dr. J.; Lok, dr. D.J.A. - DECISION - Heart failure July 2024
• Individual lifetime benefit from low-dose colchicine in patients with chronic coronary artery diseaseEuropean Journal of Preventive Cardiology - Mosterd, dr. A.; Cornel, prof. dr. J.H.; Koudstaal, dr. S.; Beelen, drs. D.P.W. - LoDoCo2 - ASCVD July 2023
• Drivers of mortality in patients with chronic coronary disease in the low-dose colchicine 2 trialInt J Cardiol - Abstract - Mosterd, dr. A.; Cornel, prof. dr. J.H.; Ronner, dr. E.; Prins, drs. F.J. - LoDoCo2 - ASCVD December 2022
• The Effect of Years-Long Exposure to Low-Dose Colchicine on Renal and Liver Function and Blood Creatine Kinase Levels: Safety Insights from the Low-Dose Colchicine 2 (LoDoCo2) TrialClinical drug investigation - Mosterd, dr. A.; Cornel, prof. dr. J.H. - LoDoCo2 - ASCVD October 2022
• Colchicine in Patients With Chronic Coronary Disease in Relation to Prior Acute Coronary SyndromeJournal of the American College of Cardiology - Fiolet, dr. A. [inactief]; Mosterd, dr. A.; Eck, dr. J.W.M. van; Beek, drs. E. van; Hartog, drs. F.R. den [inactief]; Cornel, prof. dr. J.H. - LoDoCo2 - ASCVD August 2021
• Letter to the editor: Colchicine and risk of non-cardiovascular death in patients with coronary artery disease: a pooled analysis underlying possible safety concernsEur Heart J Cardiovasc Pharmacother - Abstract - Fiolet, dr. A. [inactief]; Mosterd, dr. A. - LoDoCo2 - ASCVD March 2021
• Efficacy and safety of low-dose colchicine in patients with coronary disease: a systematic review and meta-analysis of randomized trialsEuropean Heart Journal - Fiolet, dr. A. [inactief]; Mosterd, dr. A.; Cornel, prof. dr. J.H. - LoDoCo2 - ASCVD February 2021
• Colchicine Attenuates Inflammation Beyond the Inflammasome in Chronic Coronary Artery Disease: A LoDoCo2 Proteomic SubstudyCirculation - Abstract - Fiolet, dr. A. [inactief]; The, dr. S.H.K. [inactief]; Mosterd, dr. A.; Cornel, prof. dr. J.H. - LoDoCo2 - ASCVD August 2020
• Colchicine in Patients with Chronic Coronary DiseaseNew England Journal of Medicine - Abstract - Mosterd, dr. A.; Fiolet, dr. A. [inactief]; The, dr. S.H.K. [inactief]; Lenderink, dr. T.; Hoogslag, drs. P.A.M.; Jerzewski, dr. A. [inactief]; Nierop, drs. P.R.; Swart, drs. H.P.; Schaap, dr. J.; Kuijper, dr. A.F.M.; Hessen, dr. M.W.J. van; Dirksen, dr. M.T.; Alings, dr. A.M.W.; Schut, drs. A.; Cornel, prof. dr. J.H. - LoDoCo2 - ASCVD August 2020
• Short-term effect of low-dose colchicine on inflammatory biomarkers, lipids, blood count and renal function in chronic coronary artery disease and elevated high-sensitivity C- reactive proteinPLoS One - Abstract - Fiolet, dr. A. [inactief]; Mosterd, dr. A.; Cornel, prof. dr. J.H. - LoDoCo2 - ASCVD August 2020
• The effect of low-dose colchicine in patients with stable coronary artery disease: The LoDoCo2 trial rationale, design, and baseline characteristics.Am Heart J - Abstract - Fiolet, dr. A. [inactief]; Schut, drs. A.; Mosterd, dr. A.; Cornel, prof. dr. J.H. - LoDoCo2 - ASCVD October 2019
• Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients.N Engl J Med - Abstract - Mosterd, dr. A. - SPIRE-1; SPIRE-2 - ASCVD March 2017
• Comparing LCZ696 with enalapril according to baseline risk using the MAGGIC and EMPHASIS-HF risk scores: an analysis of mortality and morbidity in PARADIGM-HF.J Am Coll Cardiol - Abstract - Mosterd, dr. A. - PARADIGM-2314; Emphasis - Heart failure November 2015
• A putative placebo analysis of the effects of LCZ696 on clinical outcomes in heart failure.Eur Heart J - Abstract - Mosterd, dr. A. - PARADIGM-2314 - Heart failure February 2015
• A putative placebo analysis of the effects of LCZ696 on clinical outcomes in heart failure.Eur Heart J - Abstract - Mosterd, dr. A. - PARADIGM-2314 - Heart failure February 2015
• Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure.Circulation - Abstract - Mosterd, dr. A. - PARADIGM-2314 - Heart failure January 2015